Ana Pena, PhD,  —

Verona Pharma released additional results of a Phase 2 trial demonstrating that maintenance treatment with its dry powder inhaler (DPI) formulation of ensifentrine (RPL554) is safe, and significantly improves lung function in people with moderate to severe chronic obstructive pulmonary disease (COPD). The trial met all its primary…

A finger-prick blood test could help guide antibiotic prescriptions for people with chronic obstructive pulmonary disease (COPD) during a flare-up, avoiding unnecessary use of antibiotics, a clinical trial shows. This simple test detects C-reactive protein (CRP), a blood marker of inflammation and bacterial infections, and resulted in 20%…

Scientists have found data to support an optimal threshold for lung function that can accurately diagnose clinically significant airflow obstruction and chronic obstructive pulmonary disease (COPD). Using information from adults across the U.S., researchers found that a 70% ratio of two spirometry indicators of lung function proved as…

Theravance Biopharma and Mylan have agreed to extend the development and commercialization of Yupelri (inhalation solution of revefenacin) — the first and only once-daily nebulized bronchodilator approved for chronic obstructive pulmonary disease (COPD) — to China and neighboring territories. The agreement could make Yupelri available…

A post-hoc analysis showed that nebulized ensifentrine (RPL544) is highly effective for relieving respiratory symptoms in chronic obstructive pulmonary disease (COPD) patients with either reversible or non-reversible airway obstruction, although the effect is greater for those with reversible disease, according to Verona Pharma, ensifentrine’s developer. Over a treatment…

The triple therapy inhaler Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) has received a positive recommendation from the European Medicines Agency (EMA)‘s Committee for Medicinal Products for Human Use (CHMP) to expand its use to a broader population of chronic obstructive pulmonary disease (COPD) patients.

Consistent support from healthcare professionals, interaction with peers, and regular exercise can help people with chronic obstructive pulmonary disease (COPD) remain physically active over the long-term, a systematic review of multiple studies shows. The report identifies both barriers and beneficial elements for physical…

Nearly 100 million Chinese adults have COPD, but most don’t know they do, a study reported. Heavy air pollution and high smoking rates are two likely reasons for the high rate, said researchers, who added that efforts to prevent and diagnose the disease early should be…

Grifols, a global healthcare company, has launched the “Look into Genetic COPD” educational campaign to raise awareness of chronic obstructive pulmonary disease (COPD) that is caused by alpha-1-antitrypsin deficiency (alpha-1), a rare genetic condition. The global healthcare company, headquartered…

The U.S. Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) submitted by Theravance Biopharma and Mylan for their collaborative compound revefenacin (TD-4208), a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) in adults. The two pharmaceutical companies are aiming to develop and…